These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31237475)

  • 1. Methods and applications of percentile estimation.
    Xia Q; Tsong Y; Weng YT
    J Biopharm Stat; 2020 Mar; 30(2):267-276. PubMed ID: 31237475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
    Shen M; Dong X; Tsong Y
    J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive clinical endpoint bioequivalence studies with sample size re-estimation based on a nuisance parameter.
    Zhu L; Sun W
    J Biopharm Stat; 2019; 29(5):776-799. PubMed ID: 31505986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity assay cut point determination using nonparametric tolerance limit.
    Zhang J; Li W; Roskos LK; Yang H
    J Immunol Methods; 2017 Mar; 442():29-34. PubMed ID: 28063769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new method for identification of outliers in immunogenicity assay cut point data.
    Zhang J; Arends RH; Kubiak RJ; Roskos LK; Liang M; Lee N; Chen CC; Yang H
    J Immunol Methods; 2020; 484-485():112817. PubMed ID: 32615125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On TIER method for assessment of individual bioequivalence.
    Ju HL
    J Biopharm Stat; 1997 Mar; 7(1):63-85. PubMed ID: 9056589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Between-Batch Bioequivalence (BBE): a Statistical Test to Evaluate In Vitro Bioequivalence Considering the Between-Batch Variability.
    Bodin J; Liandrat S; Kocevar G; Petitcolas C
    AAPS J; 2020 Sep; 22(5):119. PubMed ID: 32910283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro bioequivalence testing.
    Chow SC; Shao J; Wang H
    Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
    Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current regulatory approaches of bioequivalence testing.
    Karalis V; Macheras P
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual bioequivalence testing under 2x3 designs.
    Chow SC; Shao J; Wang H
    Stat Med; 2002 Mar; 21(5):629-48. PubMed ID: 11870806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distribution.
    Schlain B; Amaravadi L; Donley J; Wickramasekera A; Bennett D; Subramanyam M
    J Immunol Methods; 2010 Jan; 352(1-2):161-8. PubMed ID: 19891969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
    Bialer M; Midha KK
    Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis for bioequivalence review.
    Chow SC; Liu J
    J Biopharm Stat; 1997 Mar; 7(1):97-111. PubMed ID: 9056591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Equivalence assessment for interchangeability based on two-sided tests.
    Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical aspects of bioequivalence--a review.
    Pidgen AW
    Xenobiotica; 1992 Jul; 22(7):881-93. PubMed ID: 1455906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New bioequivalence studies: individual bioequivalence and population bioequivalence.
    Nakai K; Fujita M; Ogata H
    Yakugaku Zasshi; 2000 Nov; 120(11):1201-8. PubMed ID: 11190205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the ratio of means as a causal estimand in clinical endpoint bioequivalence studies in the presence of intercurrent events.
    Lou Y; Jones MP; Sun W
    Stat Med; 2019 Nov; 38(27):5214-5235. PubMed ID: 31621943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.